Printer Friendly

Malignant mesothelioma.

Byline: Ishtiaq Ahmed Salman Ahmed Tipu and Sundas Ishtiaq

SUMMARY

Malignant Mesothelioma (MM) is a rare but rapidly fatal and aggressive tumor of the pleura and peritoneum with limited knowledge of its natural history. The incidence has increased in the past two decades but still it is a rare tumor. Etiology of all forms of mesothelioma is strongly associated with industrial pollutants of which asbestos is the principal carcinogen. Mesothelioma is an insidious neoplasm arising from mesothelial surfaces i.e. pleura (65%-70%) peritoneum (30%) tunica vaginalis testis and pericardium (1%-2%). The diagnosis of peritoneal and Pleural mesothelioma is often delayed due to a long latent period between onset and symptoms and the common and nonspecific clinical presentation. The definite diagnosis can only be established by diagnostic laparoscopy or open surgery along with biopsy to obtain histological examination and immunocytochemical analysis.

Different treatment options are available but Surgery can achieve a complete or incomplete resection and Radical resection is the preferred treatment. Chemotherapy has an important role in palliative treatment. Photodynamic therapy is also an option under trial. Patients who successfully underwent surgical resection had a considerably longer median survival as well as a significantly higher 5-year survival.

Source of Data/Study Selection: The data were collected from case reports cross-sectional studies Open-label studies and phase II trials between 1973-2012.

Data Extraction: Web sites and other online resources of American college of surgeons Medline NCBI and

Medscape resource centers were used to extract data.

Conclusion: Malignant Mesothelioma (MM) is a rare but rapidly fatal and aggressive tumor with limited knowledge of its natural history. The diagnosis of peritoneal and Pleural mesothelioma is often delayed so level of index of suspicion must be kept high.

KEY WORDS: Asbestos Malignant Mesothelioma Peritoneum Surgery.

INTRODUCTION

Malignant Mesothelioma (MM) is a rare but rapidly fatal and aggressive tumor of the pleura and peritoneum with limited knowledge of its natural history. The earliest mention of a possible tumor of the chest wall (the pleura) was made in

1767 by Joseph Lieutaud the founder of pathologic anatomy in France in study of 3000 autopsies where he found two cases of pleural tumors." In 1819 RenACopyright-ThACopyrightophile-Hyacinthe Laennec the French physician based upon his understanding of the nature of pleural cells suggested the origin from the pleura. Peritoneal mesothelioma was first described in 1908 by Miller and Wynn.12 The incidence has increased in the past two decades but

still it is a rare tumour.13 The disease incidence varies geographically i.e. from less than 1 per 1000000 in Tunisia and Morocco to the highest rate in Britain Australia and Belgium i.e. 30 per 1000000 per year.3 Currently the incidence ranges from about

7 to 40 per 1000000 in industrialized Western nations depending upon the amount of asbestos exposure in the past several decades.4 Occupational and environmental asbestos exposure still remains a major causative factor. It is more common in male and the risk increases with age but this disease can appear at any age in either sex. Incidence of Malignant Peritoneal Mesothelioma (MPM) is less as compared to pleural mesothelioma and only

20% to 33% of all mesotheliomas (one fifth to one third) arise from the peritoneum.56 The diagnosis of peritoneal mesothelioma is often delayed due to a long latent period between onset and symptoms and the common and non specific clinical presentation. Due to its unusual nature the disease has not been clearly defined in terms of its natural history diagnosis or management. Moreover the treatment options are far from satisfactory. Moreover because malignant peritoneal mesothelioma (MPM) usually remains confined to the peritoneal cavity during most of its natural history so cytoreductive regional chemotherapy is an attractive option in treatment.7 Because of lack of effective treatment median survival time is 5 to 12 months only and mean symptoms-to-survival time is 345 days.26

EPIDEMIOLOGY

Mesothelioma is an insidious neoplasm arising from mesothelial surfaces i.e. pleura (65%-70%) peritoneum (30%) tunica vaginalis testis and pericardium (1%-2%).1 In the United States the overall prevalence is 1-2 cases per million or 3300 cases every year from which only 10 to 15 percent (200 -400 new cases annually) are peritoneal mesothelioma.8 In the USA incidence rates of Malignant Peritoneal Mesothelioma have remained stable over the last 30 years.89 Generally all over the world the incidence of peritoneal mesothelioma is one order of magnitude lower than pleural mesothelioma.5 Incidence is rising worldwide due to increase occupational asbestos exposure. The annual incidence of MM was approximately 1.00 cases per 100000 in 2005.9 Overall incidence of mesotheloma is expected to peak between 2015 and

2025 and among them the pleural mesothelioma accounts for most of the rising number of cases. Primary malignant mesothelioma is a highly aggressive malignancy that occurs most commonly

in older men and that has a strong association with high levels of occupational asbestos exposure.1011

It is more common in male and the incidence of peritoneal mesothelioma is 0.53.0 per million per year in male and 0.22.0 per million per year in female.15 The female component was particularly high for EPMM with male/female ratios of

1.4:1 and 1.9:1 for peritoneal and pericardium respectively and there were 2.7 male pleural MM cases for each female in ReNaM in agreement with other published case lists.5 It can occur in any age group but more common in 6th decade and only about 2% to 5% of all cases reported in the first two decades of life.12

Aetiology of all forms of mesothelioma is strongly associated with industrial pollutants of which asbestos is the principal carcinogen. Among Asbestos (primarily the crocidolite variety) is considered the main risk factor. Other risk factors in some patients are radiation exposure talc erionite or mica exposure and patients suffering from familial Mediterranean fever and diffuse lymphocytic lymphoma. Literature review shows that only 50% of patients with a peritoneal origin of MPM have a history of asbestos exposure.59

PATHOGENESIS

Regarding pathogenesis the asbestos fibers are ingested and work their way from digestive organs into the peritoneal membrane or these fibers are inhaled and travel to the peritoneal membrane via the lymphatic system. After entering the peritoneal layers they get trapped and cause changes in mesothelial cells leading to irritation and inflammation. The exact way in which asbestos fibers cause these changes is uncertain but researchers believe such changes are responsible for cancer development.1314

Most malignant mesotheliomas have complex karyotypes with extensive aneuploidy and the rearrangement of many chromosomes. The single most common karyotypic change found is the loss of one copy of chromosome 22. Other chromosomal changes commonly observed are deletions in the chromosome arms 1p 3p 9p and 6q. Several changes in the tumor suppressor genes p16 (CDKN2A) and p14 (ARF) and loss of function of neurofibromin-2 (NF2) have also been noted.15

Mesothelioma can arise from both visceral and parietal peritoneum. Grossly it appears most often as diffuse sheetlike or nodular thickening of the peritoneal surfaces and occasionally as a localized mass over the peritoneal surfaces. Multicystic mes-

othelioma occurs most commonly in female and has benign or indolent biologic behavior in the majority of patients. Multilocular cystic type arises from the pelvic peritoneal surfaces. Primary peritoneal se- rous carcinoma occurs almost exclusively in female and is histologically identical to ovarian serous car- cinoma. It may be indistinguishable from metastatic ovarian carcinoma at imaging studies.1116

CLINICAL FEATURES AND DIAGNOSIS

Clinical symptoms are usually atypical and non- specific. Commonest initial symptoms are pain (35%) distension (31%) of abdomen less frequent- ly night sweats but they often develop cachexia weight loss (69%) anorexia or ascites (77%).71217

Rarely patient presents with fever of unknown ori- gin intestinal obstruction or acute abdominal sur- gical emergency.17-19 Occasionally it is an inciden- tal diagnosis during laparoscopy. Paraneoplastic syndromes particularly associated with peritoneal mesothelioma are thrombocytosis hypercoagula- bility hypoglycemia venous thrombosis paraneo- plastic hepatopathy and a wasting syndrome.112

Majority of patient report late due to very elusive and atypical symptoms which leads to its diagno- sis in advanced stages. Moreover usually it takes a considerable time to reach the correct diagnosis and statistically mean symptoms-to-diagnosis time re- ported is about 122 days.1 Routine laboratory tests and abdominal radiograph are not helpful in mak- ing the precise diagnosis.

Ultrasound scan and Computed tomography (CT) findings are also insufficient and nonspecific to establish a diagnosis of peritoneal mesothelio- ma. However CT is useful in detection localiza- tion staging and in guiding biopsy of peritoneal masses.20 Peritoneal masses appear as heterogene- ous solid and enhancing soft-tissue masses on CT showing expansive rather than infiltrating growth pattern.16 Mainly three types of appearances are de- scribed on CT scan. The most common is Dry-pain- ful' type in which a large mass or multiple small peritoneal masses in abdominal quadrants with no signs of ascites are seen. The wet' type is as- sociated with ascities and gut distension along with widespread small nodules and plaques without any solid masses. The mixed' type is having fea- tures of both dry and wet types.21 Literature review shows insufficient data about the sonographic and MRI manifestations of peritoneal mesothelioma.

However CT scan and Ultrasonography are help- ful in providing important information during the diagnostic process.

Diagnostic laparoscopy: Due to nonspecific clinical and radiologic presentation of mesothelioma the definite diagnosis can only be established by diagnostic laparoscopy or open surgery along with biopsy to obtain histological examination and immunocytochemical analysis. The importance of diagnostic laparoscopy in the diagnosis of peritoneal mesothelioma is usually overlooked by other diagnostic modalities such as ultrasound Computed tomography and ascitic fluid cytology. Literature reports that laparoscopy can lead to dissemination of tumour to port sites and may complicate the situation.7

Role of cytology/histology: The distinction between a benign and malignant tumour and a primary from the metastatic one is another main challenge other than diagnosis. Therefore the histological and immunohistochemical examination have important role in definitive diagnosis of peritoneal mesothelioma. Ascitic fluid cytology has a low diagnostic potential due to high cytologic diversity of tumour and small number of malignant cells within the fluid. In dry type of PM fine-needle aspiration of the tumour can be used for diagnosis. Cytological markers in Immunohistochemistry used to determine whether the tissue is mesothelial in origin are Calretinin and Wilms' Tumor 1 antigen (WT1) whereas the Epithelial Membrane Antigen (EMA) is used to determine whether the tissue is malignant or not. Potentially useful serum markers for diagnosis and follow-up are the serum mesothelin-related protein (SMRP) which is elevated in more than 84% of mesotheliomas and has a 60% sensitivity at diagnosis.

Inaddition CA-125 CA 15-3 hyaluronic acid and osteopontin22 are other potential markers in the diagnosis of PM. Studies show that a positive immunostain for calretinin has markedly increased the accuracy of diagnosis.23 The malignant peritoneal mesothelioma can be diagnosed upto 80% of cases with an adequate cytologic sample and by experienced cytologists.4

Immunohistochemistry is also useful in distinguishing peritoneal mesotheliomas from primary papillary serous carcinoma of peritoneum serous ovarian carcinomas colorectal adenocarcinoma diffusely involving the peritoneum and borderline serous tumors. In particular calretinin cytokeratin and thrombomodulin are typically positive in patients with mesotheliomas and negative in serous carcinomas.24

In the absence of ascities or in case of inconclusive cytology tumor biopsy should be done to reach a diagnosis. Diagnostic accuracy increases with core

sample size because the immunohistochemical expression of tumor markers is not homogeneous within the same solid tumor section.

TREATMENT

Surgery can achieve a complete or incomplete resection and Radical resection is the preferred treatment in malignant peritoneal mesotheliomais which is associated with better prognoses and should be pursued when possible.924 Other treatments comprises of intensive loco-regional therapeutic strategies such as cytoreductive surgery hyperthermic intraoperative or early postoperative intraperitoneal chemotherapy and immunotherapy.

Radical resection is often not possible so the other alternative and better option is cytoreductive surgery which is aimed to remove as much tumor as possible.10 The surgical debulking is classified according to the Completeness of Cytoreduction Score which is also widely used in both invasive and non invasive peritoneal surface malignancies. This comprises of the evaluation of residual peritoneal seeding within the operative field and is thought to be the principle prognostic indicator. Completeness of Cytoreduction Score comprises of complete cytoreduction (CC-0) or partial with a diameter of the residual nodules less than 0.25 cm (CC-1) 0.25-2.5 cm (CC-2) and greater than 2.5 cm or confluence of tumor nodules (CC-3).2425 The CC-1 tumor is considered penetrable by intracavitary chemotherapy and is therefore designated as complete cytoreduction if perioperative intraperitoneal chemotherapy is used.

The limitation of this score is that it can be evaluated only after surgery therefore; no preoperative assessment about resectability of the tumor can be done.25 Mean Survival after cytoreductive surgery and intraperitoneal chemotherapy is 35.8 months in CC-0 or CC-1 resection and only 6.5 months with a CC-2 or CC-3 resection.25

Chemotherapy intraperitoneally or systemically has an important role in palliative treatment. Direct exposure of antitumor agent to the peritoneal surface is considered to be most effective against malignant peritoneal mesothelioma. Literature review shows that the overall response rate with a single agent combined intraperitoneal chemotherapy and continuous hyperthermic peritoneal perfusion are 13.1% 20.5% 47.4% and 84.6% respectively.26

Intraperitoneal chemotherapy can be instilled without surgery through an abdominal catheter or after surgery. Advantages of intraperitoneal chemotherapy include less systemic toxicity and

reatly enhanced drug concentrations in the peritoneal cavity.27 Continuous intraperitoneal hyperthermic perfusion after cytoreductive surgery for resectable tumors is the standard treatment at diagnosis.2428-30 In this a preheated (42.5 degrees C) perfusate with 2 or 3 antineoplastic agents (i.e. Cisplatin Mitomycin C Fluorouracil Doxorubicin and/or Paclitaxel) is continuously infused post operatively into the closed or semi-closed abdomen. Up to 12% of major morbidity is reported in literature and the most significant complications are anastomotic leaks (11%) abdominal bleeds (1.9%) and sepsis (1.9%).2430 About 12% operative mortality is also reported. Cisplatin is the most studied drug with activity in 25% of patients.27

Regarding systemic chemotherapy literature shows that the Pemetrexed in combination with cisplatin has improved survival in patients with peritoneal mesothelioma as in pleural mesothelioma.3132 Data from uncontrolled studies recommends it as a standard of care for patients with unresectable malignant mesothelioma. About 71.2% of the disease control rate reported which includes partial responses or stable disease. Complete responses are not reported from this chemotherapy.33 Other regimens like Vinorelbine and Gemcitabine either alone or combined with platinum compounds are also used for unresectable disease.32 Among them the response rate of Vinorelbine alone is 24%34 whereas the Irinotecan35 and Gefinitib36 have not proved effective when used alone. Overall survival of 17 and 92 months (70%) 5-year overall survival 63% disease-free survival and 51% progression-free survival after cytoreductive surgery and continuous hyperthermic peritoneal perfusion with Cisplatin Fluorouracil and Paclitaxel reported in literature.28

Over the past decade the management of perito- neal mesothelioma has evolved similarly to ovarian cancer treatment i.e. cytoreductive surgery heated intraoperative intraperitoneal chemotherapy (HIIC) with cisplatin doxorubicin and early postopera- tive intraperitoneal paclitaxel. These perioperative treatments are followed by adjuvant intraperito- neal Paclitaxel and second-look cytoreduction. This multimodality treatment i.e. cytoreductive surgery and intraperitoneal chemotherapy has resulted in a median survival of 50 to 60 months.2123

Radiotherapy has a very limited role in treatment of peritoneal mesothelioma so it is not currently used.37

Immunotherapy is being used on an experimental basis at present mainly for pleural mesothelioma.

Mainly the Humanized anti-CD3 antibodies (OKT3) Cytotoxic T lymphocytes (CTL) Interferon alfa-2a and autovaccine have been used anecdotally for palliation of advanced peritoneal mesothelioma but further studies are needed before this therapy can be recommended.38-40

Gene therapy is currently another exploring way by the genetic researchers to safely treat mesothelioma patients. Suicide gene therapy is one of the most promising forms of gene therapy for the treatment of mesothelioma. Clinical trials conducted at the University of Pennsylvania Medical Center shows that the suicide gene therapy is effective in reducing the size and severity among four of the 34 patients studied. Another type of gene therapy is under trial in which modified viruses are used to deliver immune system molecules called cytokines which control and direct immune response. When introduced through gene therapy these cytokines can help the immune system to mount an attack against cancer cells.4142

Photodynamic therapy is also an option under trial in which medical researchers seek to improve the efficacy and use in the treatment of mesothelioma. Researchers hope to develop photosensitizers that specifically target cancer cells and have more toxic reactions. They also hope to find a more effective means of administering the necessary light which can penetrate tissue and treat larger tumors.43

PROGNOSIS

Prognosis is mainly determined by gender stage of clinical presentation and the level of completeness of cytoreduction. A significant difference between women and men (13 months vs.

6 months respectively) (Pless than 0.001) has been reported in literature.44 Studies have proved that mean survival has improved by the use of intraperitoneal chemotherapy. Patients who successfully underwent surgical resection had a considerably longer median survival (20 months vs. 4 months Pless than 0.001) as well as a significantly higher 5-year survival (28% vs.

12% Pless than 0.001). Multivariate analysis identified that a poorly differentiated tumor grade failure to undertake surgical resection advanced age and male gender were all independent predictors of poorer outcome.9

Literature review conclude that the Pericardial and peritoneal MM have worse prognosis (median survival 5e6.9 months) than pleural MM (median survival 7.9e10 months). A recent analysis reported shorter survival for the most peritoneal MM cases.

CONCLUSION

Malignant Mesothelioma (MM) is a rare but rapidly fatal and aggressive tumor with limited knowledge of its natural history. The diagnosis of peritoneal and Pleural mesothelioma is often delayed due to a long latent period between onset and symptoms and the common and nonspecific clinical presentation. A considerably high level of index of suspicion must be borne in mind and further studies are required to reach the definitive diagnosis.

REFERENCES

1. Bridda A Padoan I Mencarelli R Frego M. Peritoneal

Mesothelioma: A Review. Med Gen Med. 2007;9(2):32.

2. Cunha P Luz Z Seves I. Malignant peritoneal mesothelioma

diagnostic and therapeutic difficulties. Acta Med Port.

2002;15:383386.

3. Bianchi C Bianchi T. Malignant mesothelioma: global

incidence and relationship with asbestos. Industrial Health.

2007;45(3):379387.

4. Robinson BW Lake RA. Advances in malignant

mesothelioma. N Engl J Med. 2005;353:15911603.

5. Boffetta P. Epidemiology of peritoneal mesothelioma: a

review. Annals Oncol. 2007;18(6):985990.

6. De Pangher Manzini V. Malignant peritoneal mesothelioma.

Tumori. 2005;91:15.

7. Ahmed I Koulaouzidis A Iqbal J Tan WC. Malignant

peritoneal mesothelioma as a rare cause of ascites: a case

report. J Med Case Reports. 2008;2:121.

8. Teta MJ Mink PJ Lane E. US mesothelioma pattern 1973-

2002: indicators of change and insight into background rate.

Eu J Cancer Prev. 2008;17:525.

9. Rodriguez D Cheung MC Housri N Koniaris LG.

Malignant abdominal mesothelioma: defining the role of

surgery. J Surg Oncol. 2009;99(1):51.

10. Brigand C Monneuse O Mohamed F. Peritoneal

mesothelioma treated by cytoreductive surgery and

intraperitoneal hyperthermic chemotherapy: results of a

prospective study. Ann Surg Oncol. 2006;13:405412.

11. Levy AD Arnaiz J Shaw JC Sobin LH. From the

archives of the AFIP: primary peritoneal tumors: imaging

features with pathologic correlation. Radiographics.

2008;28(2):583.

12. Baker PM Clement PB Young RH. Malignant peritoneal

mesothelioma in women: a study of 75 cases with emphasis

on their morphologic spectrum and differential diagnosis.

Am J Clin Pathol. 2005;123:724737.

13. Galateau-Salle Francoise. Pathology of Malignant

Mesothelioma. Springer-Verlag London Limited:

London. 2006.

14. Borasio P Berruti A BillACopyright A. Malignant pleural

mesothelioma: clinicopathologic and survival characteristics

in a consecutive series of 394 patients. Eur J Cardiothorac

Surg. 2008;33(2):307313.

15. Murthy SS Testa JR. Asbestos chromosomal

deletions and tumor suppressor gene alterations

in human malignant mesothelioma. J Cell Physiol.

1999;180(2):150-157.

16. Busch JM Kruskal JB Wu B. Armed Forces Institute of

Pathology Best cases from the AFIP. Malignant peritoneal

mesothelioma. Radiographics. 2002;22:15111515.

17. American Cancer Society. Malignant Mesothelioma Overview. 2012. Retrieved from website: http:// www.cancer.org/acs/groups/cid/documents/ webcontent/003062-pdf.pdf.

18. International Mesothelioma Symposium Presentation. 2011

Retrieved from: website: http://www.curemeso.org/site/c.

kkLUJ7MPKtH/b.7634491/k.86EF/2011_Symposium_

Presentations/apps/nl/newsletter.asp.

19. American Cancer Society. Malignant Mesothelioma

Overview. 2012. Retrieved from website: http://

www.cancer.org/acs/groups/cid/documents/

webcontent/003062-pdf.pdf

20. Pickhardt PJ Bhalla S. Primary neoplasms of peritoneal

and sub-peritoneal origin: CT findings. Radiographics.

2005;25:983995.

21. Sugarbaker PH Acherman YI Gonzalez-Moreno S.

Diagnosis and treatment of peritoneal mesothelioma: The

Washington Cancer Institute experience. Semin Oncol.

2002;29:5161.

22. Edwards JG Abrams KR Leverment JN. Prognostic factors

for malignant mesothelioma in 142 patients: validation of

CALGB and EORTC prognostic scoring systems. Thorax.

2000;55(9):731735.

23. Sterman DH. Advances in management of mesothelioma.

Respirology. 2005;10:266-283.

24. Kusamura S Younan R Baratti D. Cytoreductive surgery

followed by intraperitoneal hyperthermic perfusion:

analysis of morbidity and mortality in 209 peritoneal surface

malignancies treated with closed abdomen technique.

Cancer. 2006;106:11441153.

25. Konstantinidis IT Young C Tsikitis VL Lee E Jie T Ong ES.

Cytoreductive surgery and hyperthermic intraperitoneal

chemoperfusion: The University of Arizona early

experience. World J Gastrointest Surg. 2012;27(6):135-140.

26. Hotta T Taniguchi K Kobayashi Y. Chemotherapy and

serum hyaluronic acid levels in malignant peritoneal

mesothelioma. Hepatogastroenterology. 2004;51:10731083.

27. Le DT Deavers M Hunt K Malpica A Verschraegen

CF. Cisplatin and irinotecan (CPT-11) for peritoneal

mesothelioma. Cancer Invest. 2003;21:682689.

28. Deraco M Kusamura S Baratti D Casali P Zaffaroni

N. Peritoneal mesothelioma: results of a complicated

and aggressive procedure incorporating peritonectomy

and intraperitoneal hyperthermic chemotherapy and

prospects derived from bench-to-bedside research. Tumori.

2003;89:5657.

29. Baratti D Kusamura S Cabras AD Laterza B Balestra MR

Deraco M. Lymph node metastases in diffuse malignant

peritoneal mesothelioma. Ann Surg Oncol. 2010;17(1):45-53.

30. Casado-Adam A Alderman R Stuart OA Chang D

Sugarbaker PH. Gastrointestinal complications in 147

consecutive patients with peritoneal surface malignancy

treated by cytoreductive surgery and perioperative

intraperitoneal chemotherapy. Int J Surg Oncol.

2011;2011:468698.

31. Sugarbaker PH Yan TD Stuart OA Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:68691.

32. Garcia-Carbonero R Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:676681.

33. Janne PA Wozniak AJ Belani CP. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:4046.

34. Hada M Kazuhiro M. A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide celecoxib vinorelbine and CDDP Gan To Kagaku Ryoho. 2004;31:21912194.

35. Kindler HL Herndon JE Zhang C Green MR. Cancer and Leukemia Group B Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005;48:423428.

36. Govindan R Kratzke RA Herndon JE. For the Cancer and Leukemia Group B (CALGB 30101) Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11:23002304.

37. Hesdorffer ME Chabot JA Keohan ML Fountain K Talbot S Gabay M et al. Combined resection intraperitoneal chemotherapy and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31(1):49-54.

38. Robinson BW Musk AW Lake RA. Malignant

mesothelioma. Lancet. 2005;366:397408.

39. Schlom J. Therapeutic cancer vaccines: Current status and

moving forward. J Natl Cancer Inst. 2012;104(8):599-613.

40. Hodge JW Schlom J Abrams SI. Vaccines and

immunostimulants. In: Kufe DW Bast RC Hait WN Hong

WK Pollock RE Weichselbaum RR Holland JF Frei E eds.

Cancer Medicine 7. Hamilton Ontario: BC Decker Inc.

2006:786801.

41. American Cancer Society. (2012 January 12). Whats New

in Malignant Mesothelioma Research 2012 Retrieved

from web site: http://www.cancer.org/Cancer/

M alignantM es othelio m a/Detailed Guid e/ m alignant-

mesothelioma-new-research

42. Abramson Cancer Center of the University of Pennsylvania.

Gene Therapy: The Basics. 2010 Retrieved from

website: http://www.oncolink.org/treatment/article.

cfmc=15 and s=110 and id=323

43. Demmy TL. Surgery and Photodynamic Therapy in

Treating Patients With Malignant Mesothelioma. 2011.

Retrieved from website: http://clinicaltrials.gov/ct2/

show/NCT00054002

44. Mirabelli D Roberti S Gangemi M. Survival of peritoneal

malignant mesothelioma in Italy: a population-based study.

Int J Cancer. 2009;124:194e200.
COPYRIGHT 2013 Asianet-Pakistan
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Pakistan Journal of Medical Sciences
Date:Dec 31, 2013
Words:4185
Previous Article:Frequency of methicillin-resistant Staphylococcus aureus nasal colonization among patients suffering from methicillin resistant Staphylococcus aureus...
Next Article:Effects of carotid endarterectomy and carotid artery stenting on high-risk carotid stenosis patients.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters